Market Overview

UPDATE: Stifel Reiterates on Aerie Pharmaceuticals as Timelines Are on Track

Related AERI
Watch These 10 Huge Call Purchases In Thursday Trade
Benzinga's Option Alert Recap From February 22
Biotech Forum Daily Digest: Can Aerie Pharmaceuticals Continue To Rally? Spotlight On OncoMed Pharmaceuticals (Seeking Alpha)

In a report published Wednesday, Stifel analyst Annabel Samimy reiterated a Buy rating on Aerie Pharmaceuticals (NASDAQ: AERI), and raised the price target from to $22.00 to $24.00.

In the report, Stifel noted, “AERI reported 4Q13 revenue loss of $10.3mn translating to $0.62 loss-per-share with initial AR-13324/Rhopressa launch expected by 2017. Importantly, PG324/Roclatan's Phase 2b trial results are expected by early 3Q14. Additionally, AERI plans to initiate their Phase 3 for Rhopressa in 3Q14 (results mid-2015). Given recent episcleral venous pressure findings, Rhopressa's role in lowering pressure in normotensive patients (IOPs #26 mmHg, representing ~80% of patients, and IOPs #21 mmHg representing ~60%), AERI can now better position Rhopressa as front-line agent, with added cosmetic advantages over PGAs.

"As of February 28th, AERI has $67.6mn in cash, expected to last through Rhopressa's NDA filing and Roclatan's Phase 3 preparation. Overall, AERI continues to perform ahead of expectations and we raise our TP to $24 on stronger Rhopressa positioning.”

Aerie Pharmaceuticals closed on Tuesday at $21.89.

Latest Ratings for AERI

Feb 2017Cowen & Co.Initiates Coverage OnOutperform
Feb 2017Roth CapitalInitiates Coverage OnBuy
Dec 2016Canaccord GenuityAssumesBuy

View More Analyst Ratings for AERI
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Price Target Analyst Ratings


Related Articles (AERI)

View Comments and Join the Discussion!